MYnd Analytics and Emmaus Life Sciences Announce Merger and Spin-off Transaction
Emmaus’ commercial lead product Endari™ (L-glutamine oral powder) is FDA approved to reduce the acute complications of sickle cell disease Endari addresses a $3 billion worldwide market MISSION VIEJO, Calif. and TORRANCE, Calif., Jan. 07, 2019 (GLOBE …